Controlled Drug Delivery by Biodegradable Poly(Ester) Devices: Different Preparative Approaches

Jain, Rajeev A.; Shah, Navnit; Malick, A. Waseem; Rhodes, C. T.

doi:10.3109/03639049809082719

Cited by 242 publications

(142 citation statements)

References 137 publications

Supporting

Mentioning

129

Contrasting

Unclassified

Order By: Relevance

“…Further improvement of the bone healing process has been attained by combining bio-molecules such as growth factors (e.g. bone morphogenic proteins) with biodegradable devices (Jain et al, 1998). The last move forward has been the creation of tissue engineering constructs composed of a biodegradable porous structure, a biological stimulus such as growth factors and a biological component such as autologous cells.…”

Section: Eglin and M Alinimentioning

confidence: 99%

Degradable polymeric materials for osteosynthesis: Tutorial

Eglin

Alini²

2008

eCM

111

View full text Add to dashboard Cite

This report summarizes the state of the art and recent developments and advances in the use of degradable polymers devices for osteosynthesis. The current generation of biodegradable polymeric implants for bone repair utilising designs copied from metal implants, originates from the concept that devices should be supportive and as "inert" substitute to bone tissue. Today degradable polymeric devices for osteosynthesis are successful in low or mild load bearing applications. However, the lack of carefully controlled randomized prospective trials that document their efficacy in treating a particular fracture pattern is still an issue. Then, the choice between degradable and non-degradable devices must be carefully weighed and depends on many factors such as the patient age and condition, the type of fracture, the risk of infection, etc. The improvement of the biodegradable devices mechanical properties and their degradation behaviour will have to be achieved to broaden their use. The next generation of biodegradable implants will probably see the implementation of the recent gained knowledge in cellmaterial interactions and cells therapy, with a better control of the spatial and temporal interfaces between the material and the surrounding bone tissue.

show abstract

Section: Eglin and M Alinimentioning

confidence: 99%

Degradable polymeric materials for osteosynthesis: Tutorial

Eglin

Alini²

2008

eCM

111

View full text Add to dashboard Cite

show abstract

“…Both polymers have been approved by FDA for drug delivery (Jain et al, 1998;Södergård and Stolt, 2002;Panyam and Labhasetwar, 2003) and widely used as excipients in nanoprecipitation processes (Jain, 2000;Lu and Chen, 2004). The main objectives of this study were: (i) to make appropriate choice of good and poor solvent of the polymers, (ii) to observe the mixing process in situ using a microscope video system, and (iii) to investigate the effect of operating parameters, system geometry, and surfactants on the final particle size distribution.…”

Section: Introductionmentioning

confidence: 99%

Preparation of biodegradable polymeric nanoparticles for pharmaceutical applications using glass capillary microfluidics

Othman

Vladisavljević

Nagy

2015

Chemical Engineering Science

View full text Add to dashboard Cite

The aim of this study was to develop a new microfluidic approach for the preparation of nanoparticles with tuneable sizes based on micromixing / direct nanoprecipitation in a coaxial assembly of tapered-end glass capillaries. The organic phase was 1 wt% poly(-caprolactone) (PCL) or poly(dl-lactic acid) (PLA) in tetrahydrofuran and the antisolvent was Milli-Q water.The size of nanoparticles was precisely controlled over a range of 190-650 nm by controlling phase flow rates, orifice size and flow configuration (two-phase co-flow or countercurrent flow focusing). Smaller particles were produced in a flow focusing device, because the organic phase stream was significantly narrower than the orifice and remained narrow for a longer distance downstream of the orifice. The mean size of PCL particles produced in a flow focusing device with an orifice size of 200 m, an organic phase flow rate of 1.7 mL h -1 and an aqueous-toorganic flow rate ratio of 10 was below 200 nm. The size of nanoparticles decreased with decreasing the orifice size and increasing the aqueous-to-organic phase flow rate ratio. Due to *Revised Manuscript Click here to view linked References 2 higher affinity for water and amorphous structure, PLA nanoparticles were smaller and exhibited a smoother surface and more rounded shape than PCL particles.

show abstract

“…The precision was determined from the RSD of predicted concentrations that were obtained from the regression equation. The values of limit of quantitation (LOQ) and limit of detection (LOD) of deslorelin were calculated using standard calibration curve as 3.3 σ/S and 10 σ/S, respectively, where S is the slope of the calibration curve and σ is the standard deviation of the response (Jain et al, 1998;Jain et al, 2000;. The capability of ISFM system to form microspheres in-situ was confirmed in phosphate buffer solution (Jain et al, 2000).…”

Section: Precisionmentioning

confidence: 99%

“…The mixture was continuously homogenized at 10,000 rpm, using an Ultra Turrax ® for 10 min, to form PLGA microglobules dispersed in the continuous oil phase and stabilized by Span 80 & aluminiummonostearate. The system thus obtained was termed as an 'ISFM system ' (Jain et al, 1998;Jain et al, 2000;. The capability of ISFM system to form microspheres in-situ was confirmed in phosphate buffer solution (Jain et al, 2000).…”

mentioning

confidence: 92%

Development and optimization of in-situ forming microparticles for long term controlled delivery of deslorelin acetate

Kapoor¹,

Katare²,

Kaurav³

et al. 2018

J App Pharm Sci

View full text Add to dashboard Cite

Deslorelin is a nonapeptide analogue of the natural gonadotropin releasing hormone or luteinizing hormone releasing hormone used to treat prostate cancer, endometriosis and uterine fibroids. In-situ forming microparticles were developed for deslorelin using smart, biodegradable polymer i.e. PLGA. Response surface, I-optimal design were used to design, formulate and characterize different formulations of deslorelin. To determine the optimized formulation, numerical and graphical optimization techniques were employed. The resulting optimized formulation was evaluated for other physicochemical parameters viz., rheology, particle size distribution, surface morphology of the particles, peptide conformation stability in the formulation and stability study at different environmental conditions. It was concluded that the optimized deslorelin acetate ISFM formulation effectively extended the peptide release for 30 days while maintaining its conformational stability during the period of study. The optimized ISFM formulation was found to be stable at 5°C ± 2°C and 25°C ± 2°C during 6 months stability studies. Key words:PLGA, Implants, Optimal Design, Peptide and Protein Delivery. INTRODUCTIONUnlike conventional small molecules, therapeutic proteins are difficult to be administered orally because they are liable to degradation by the harsh gastric environment, hepatic metabolism and short half-lives thereby necessitating frequent administration of high doses by parenteral route (Cleland et al., 2001;Fu et al., 2000;Robinson and Talmadge, 2002). This may lead to major compliance issues in case of geriatric and pediatric patients on replacement therapy. To improve the patient compliance and convenience, prefilled syringes, needleless injectors, auto injectors, pen devices and syringe injectors have been introduced in the market (Arslanoglu et al., 2000;Oberye et al., 2000). However, even these modified and improved versions have their own limitations like higher cost and complex manufacturing process. Moreover, they do not address the requirement for decrease in the dosing frequency. * Corresponding AuthorDeepak N Kapoor, School of Pharmaceutical Sciences, Shoolini University of Biotechnology and Management Sciences, Solan-173212, H.P., India. Email: deepakpharmatech @ gmail.com Deslorelin is a luteinizing hormone releasing hormone (LHRH)/Gonadotropin releasing hormone (GnRH) analogue which is 144 times more potent than the native LHRH/GnRH (Suprelorin, 2010). It is used to treat prostate cancer, endometriosis, uterine fibroids, precocious puberty and breast cancer (Kiesel et al., 2002). Treatment with GnRH or its agonists require long term therapy primarily by parenteral route (i.v., s.c. or i.m.) since these peptides are vulnerable to gastrointestinal peptidase degradation which makes them inappropriate for oral administration with only 0.1% bioavailability (Conn and Crowley, 1991; Chrisp and Goa, 1990). Intra-nasal administration of deslorelin is also ineffective and inconstant, with only 4 to 21% being available rel...

show abstract

Controlled Drug Delivery by Biodegradable Poly(Ester) Devices: Different Preparative Approaches

Cited by 242 publications

References 137 publications

Degradable polymeric materials for osteosynthesis: Tutorial

Degradable polymeric materials for osteosynthesis: Tutorial

Preparation of biodegradable polymeric nanoparticles for pharmaceutical applications using glass capillary microfluidics

Development and optimization of in-situ forming microparticles for long term controlled delivery of deslorelin acetate

Contact Info

Product

Resources

About